Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Thermostable vaccines to enable global immunization

Project description

Innovative formulation protects vaccines at high temperatures

Vaccination is the most effective method of stimulating the immune system to recognise specific disease-causing microorganisms and prevent infection. Vaccines contain various agents such as weakened microorganisms, proteins or nucleic acids that may be damaged when exposed to high temperatures. However, maintaining low temperatures during transport until vaccine administration poses a significant challenge, especially in resource-poor countries. The scope of the ERC-funded GLOBEVAC proof-of-concept project is to validate a novel formulation that makes vaccines thermostable even at high temperatures for long periods of time. This formulation is expected to maintain vaccine effectiveness and facilitate its distribution in all parts of the world.

Objective

With GLOBEVAC we present a novel solution to make vaccines thermostable, enabling global immunization by avoiding the need for cold chain logistics.

Vaccines are one of the most successful public health interventions to reduce the morbidity and mortality of infectious diseases. To ensure the safety and effectiveness of a vaccine, the production and distribution of almost all vaccines require what is called a cold chain, where the vaccine is continuously kept below certain threshold temperatures, sometimes as low as 80C. The need for such a cold chain inhibits cost-efficient and rapid distribution of vaccines and significantly reduces immunization in low resource settings. Our GLOBEVAC approach consists of storing the vaccines in a novel formulation making them thermostable for weeks when kept at temperatures as high as 40C. Preliminary in vitro data has shown that our GLOBEVAC solution can be applied for several classes of vaccines: GLOBEVAC formulated adenovirus-based vaccines and vaccines based on enveloped viruses, that were stored at 40C, were as active and functional as the fresh ones kept at -80C.

In this ERC PoC we will technically validate our novel formulation for different classes of vaccines. Next to that, we will explore the commercial potential of GLOBEVAC by developing an intellectual property strategy and performing an extensive market analysis that will finally lead to the development of a tailored business strategy.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-POC2

See all projects funded under this call

Host institution

HELSINGIN YLIOPISTO
Net EU contribution
€ 150 000,00
Address
FABIANINKATU 33
00014 Helsinki
Finland
Region
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)